3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Erectile Dysfunction
1
Childhood Solid Tumor
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
7
Radiosurgery
6
Bevacizumab
6
pembrolizumab
4
Oxaliplatin
4
Cryosurgery
4
atezolizumab
3
Radiotherapy, Conformal
3
Nivolumab
3
Ipilimumab
3
Fluorouracil
3
Cyclophosphamide
3
tremelimumab
2
spartalizumab
2
lenvatinib
2
fludarabine
2
Leucovorin
2
Injections
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Capecitabine
2
yttrium chloride
1
vofatamab
1
toripalimab
1
tocilizumab
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liver Neoplasms
×
Cell- and Tissue-Based Therapy
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled